Monoclonal Antibody to Transthyretin (TTR)
| Code | Size | Price |
|---|
| MAA726Hu22-20ul | 20ul | £85.00 |
Quantity:
| MAA726Hu22-100ul | 100ul | £156.00 |
Quantity:
| MAA726Hu22-200ul | 200ul | £210.00 |
Quantity:
| MAA726Hu22-1ml | 1ml | £480.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
- Immunocytochemistry (ICC)
- Immunofluorescence (IF)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
TBPA; PA; PLB; ATTR; TTR; Transthyretin; Prealbumin Amyloidosis Type I; Transports Thyroxine and Retinol
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Prealbumin
Potency (Clone Number):
D2
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:500-2000<br/>Immunohistochemistry: 5-20ug/mL;1:50-200<br/>Immunocytochemistry: 5-20ug/mL;1:50-200<br/>Optimal working dilutions must be determined by end user.
References
https://www.ncbi.nlm.nih.gov/pubmed/32393063;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Transthyretin (TTR) | RPA726Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||